Reported Rates of Intraocular Inflammation with Intravitreal Aflibercept Administered via Pre-Filled Syringe or from Vials in Clinical Practice Between 2012 and 2022

• Published in: Clinical ophthalmology (Auckland, N.Z.) N.Z.), 2023-01, Vol.17, p.385-390
• Main Authors: Schmidt-Ott, Ursula, Fitzpatrick, Scott, Hasanbasic, Zoran, Leal, Sergio, Morgan-Warren, Peter, Zhang, Xin, Johnson, Kristian T
• Format: Article
• Language: English
• Subjects: Age; anti vegf; Care and treatment; Clinical medicine; Clinical trials; drug-related side effects and adverse reactions; Edema; eye; Health aspects; Hypodermic needles; Hypodermic syringes; Hypothesis testing; Inflammation; injection; ioi; Marketing; Medical personnel; Medical supplies; Patients; Pharmacovigilance; Professionals; Short Report; Syringes; Vascular endothelial growth factor; Visual acuity
• ISSN: 1177-5467; 1177-5483; 1177-5483
• DOI: 10.2147/OPTH.S393519

To determine the reported rates of intraocular inflammation (IOI) in patients treated with intravitreal aflibercept (IVT-AFL) 2 mg in routine clinical practice (ie, outside interventional studies), across all indications and within all countries (excluding the United States), with access to either the vial presentation or pre-filled syringe (PFS). A search was conducted using the Bayer EYLEA Global Safety Pharmacovigilance Database for reported cases of IOI and IVT-AFL use between October 2012 and March 31, 2022. With more than 10 years of post-marketing experience with the IVT-AFL vial presentation (>25 million sold units), and over 2 years of experience with the PFS of IVT-AFL (>6.7 million sold units) the rate of any IOI, including endophthalmitis, outside the United States was 0.3 events per 10,000 units for the PFS and 1.2 events per 10,000 units for the vial presentation. The event rates specifically for endophthalmitis were 0.1 per 10,000 units for the IVT-AFL PFS and 0.6 per 10,000 units for the IVT-AFL vial presentation. In patients with retinal diseases treated in routine clinical practice with IVT-AFL either from a vial or the PFS, medically important adverse events of IOI, and in particular, endophthalmitis, are infrequently reported events. Numerically, reported rates of IOI and endophthalmitis are low for the vial presentation and even lower for the PFS.